There's still complete chaos in NASDAQ:GERN , but the quarterly report is approaching, and the market is running out of time to ignore the stock's true valuation. Let's see what happens in the next 9 days. In my view, the chart currently looks like this. A return to the mean looks very promising...
Or is it just another stock whose value will be wiped out in the next few quarters, and the company will simply lose its listing on the Nasdaq?
Investors are likely to get an answer to this question today, before the market opens, when NASDAQ:GERN reports its quarterly earnings.
The company has an approved drug and has already begun commercialization, with a...
We’ve reached the lower boundary—whether this marks the start of a prolonged sell-off or a rebound point doesn’t matter right now. In the next couple of weeks, we’ll trade higher before the true extent of the damage becomes clear. This is a good spot to start buying the market.
Tesla's shares are no longer excessively expensive, but they are still not cheap. 😅
Hopefully, we can see the price closer to $240 amid all the negativity. 🤞📉
Let’s look at the financial metrics sequentially:
- Revenue grew 73% YoY, reaching $427M last quarter.
- Next quarter, the company forecasts revenue of just $370M, but this is due to annual seasonality, which was particularly noticeable two years ago when revenue dropped from $200M to $163M.
- The Q4 2025 forecast projects revenue of $556M—a new company...
